A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by HealthCare Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
HealthCare Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01711671
First received: October 18, 2012
Last updated: June 26, 2014
Last verified: June 2014

October 18, 2012
June 26, 2014
May 2013
June 2015   (final data collection date for primary outcome measure)
  • Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV) [ Time Frame: Pre-study to after 6 months of therapy ] [ Designated as safety issue: No ]
    SUV as measured by NaF-PET/CT in both myeloma bone lesions and normal bone
  • Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki) [ Time Frame: Pre-study to after 6 months of therapy ] [ Designated as safety issue: No ]
    Ki as measured by NaF-PET/CT in both myeloma bone lesions and normal bone
  • F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV) [ Time Frame: Pre-study to after 6 months of therapy ] [ Designated as safety issue: No ]
    SUV as measured by FDG-PET/CT in both myeloma bone lesions and normal bone
  • Number of patients with treatment emergent adverse events [ Time Frame: Baseline to study completion (approximately 7 months) ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01711671 on ClinicalTrials.gov Archive Site
  • Overall response rate (ORR) [ Time Frame: Baseline to study completion (approximately 7 months) ] [ Designated as safety issue: No ]
  • Progression free survival (PFS) [ Time Frame: Baseline to study completion (approximately 7 months) ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: Baseline to study completion (approximately 7 months) ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Baseline to study completion (approximately 7 months) ] [ Designated as safety issue: No ]
  • Pharmacokinetics: area under the concentration - time curve (AUC) of a single dose of DKN-01 [ Time Frame: Dosing interval of 2 weeks following the first dose in Cycle 1 ] [ Designated as safety issue: No ]
  • Pharmacokinetics: maximum plasma concentration (Cmax) of a single dose of DKN-01 [ Time Frame: Dosing interval of 2 weeks following the first dose in Cycle 1 ] [ Designated as safety issue: No ]
  • Pharmacokinetics: trough DKN-01 concentrations on Cycle 2 and Cycle 3 [ Time Frame: Cycle 2 Day 1 Pre-dose, Cycle 3 Day 1 Pre-dose ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
  • Drug: DKN-01 300 mg
    300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
  • Drug: DKN-01 600 mg
    600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
  • Drug: Standard of Care
    Current approved standard of care
    Other Names:
    • Lenalidomide
    • Revlimid
    • Dexamethasone
  • Experimental: DKN-01 300mg
    DKN-01 plus lenalidomide (Revlimid)/dexamethasone
    Intervention: Drug: DKN-01 300 mg
  • Experimental: DKN-01 600mg
    DKN-01 plus lenalidomide (Revlimid)/dexamethasone
    Intervention: Drug: DKN-01 600 mg
  • Active Comparator: Standard of Care
    Lenalidomide (Revlimid)/dexamethasone
    Intervention: Drug: Standard of Care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
August 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Relapsed or refractory Multiple Myeloma (MM)

    a. Treated with at least 1 prior regimen for myeloma

    1. Prior treatment with bortezomib (Velcade) is acceptable with a wash-out of 2 weeks
    2. Treatment with prior autologous transplant is permitted
    3. If a transplant is used as consolidation following chemotherapy, without intervening disease progression, it will be considered 1 line of treatment with the preceding chemotherapy
  • Diagnosis of symptomatic MM as defined by the International Myeloma Working Group (IMWG) :

    1. Second line or greater/Refractory/Relapsed, Stage I, Stage II, Stage III
    2. Measureable disease as indicated by monoclonal protein in the serum of greater than or equal to (≥) 1 grams per deciliter (g/dL), involved serum free light chain assay ≥10 mg/dL (≥100 mg/L) provided the serum free light chain ratio is abnormal; monoclonal light chain in the urine protein electrophoresis of ≥ 200 mg/24 hours, or measurable plasmacytoma
  • At least 1 osteolytic bone lesion
  • Disease-free of active second/secondary or prior malignancies for equal to or over 5 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast
  • Ambulatory patients greater than or equal to (≥) 30 years of age
  • Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
  • Estimated life expectancy of ≥ 26 weeks
  • Adequate organ function including:

    1. Hematologic:

      1. Absolute neutrophil count (ANC) greater than or equal to (≥) 1000/microliter
      2. Platelet (PLT) count ≥ 75,000/microliter
      3. Hemoglobin (Hgb) ≥ 8.0 g/dL
    2. Acceptable coagulation status:

      1. Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.2 x the upper limit of normal (ULN) unless receiving anticoagulation therapy. If receiving anticoagulation therapy, eligibility will be based upon International Normalization Ratio (INR)
      2. International normalized ratio (INR) less than or equal to (≤) 1.6 (unless receiving anticoagulation therapy)

        • If receiving warfarin: INR ≤ 3.0 (and no active bleeding, [i.e., no bleeding within 14 days prior to first dose of study therapy])
    3. Hepatic:

      1. Bilirubin ≤ 1.5 x ULN
      2. Alanine Transaminase (ALT) and Aspartate Transaminase (AST) ≤ 2.5 x ULN (if liver metastases are present, then ≤ 5 x ULN is allowed)
    4. Renal:

      1. Calculated creatinine clearance ≥ 45 mL using the Cockcroft and Gault Method
  • Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 10 to 14 days and again within 24 hours of starting study drug

    1. WCBP must agree to have pregnancy tests monthly (every 14 days for women with irregular cycles) while on study drug and 4 weeks after the last dose of study drug
    2. Men must also agree to use a condom if their partner is of child bearing potential, even if they have had a successful vasectomy
    3. Males and females with reproductive potential must agree to use medically approved contraceptive precautions starting 4 weeks prior to initiation of the therapy and during the trial and for 18 months following the last dose of study drug
    4. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Provide written informed consent prior to any study-specific procedures
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion Criteria:

  • Received treatment with an investigational drug, which has not received regulatory approval for any indication, within 28 days of study treatment with DKN-01
  • Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of entry
  • Previously treated with an anti-Dickkopf-1 (anti-DKK-1) or antibody therapy, or have had a significant allergy to a known pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient
  • Received radiation therapy, surgery, or chemotherapy within 2 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C)
  • Received bisphosphonates (e.g., etidronate, clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate) within 2 weeks prior to study entry
  • Symptomatic central nervous system (CNS) malignancy or metastasis. Patients with treated CNS metastases are eligible provided their disease is radiographically stable, asymptomatic, and they are not currently receiving corticosteroids and/or anticonvulsants. Screening of asymptomatic patients without a history of CNS metastases is not required
  • Have a history of major organ transplant (for example: heart, lungs, liver, and kidney)
  • Are pregnant or nursing
  • Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb)
  • Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection, within 7 days of study entry requiring systemic therapy
  • Serious cardiac condition such as myocardial infarction within the past 6 months, unstable angina, or Class III or IV congestive heart failure as defined by the New York Heart Association (NYHA); have ECG abnormalities including baseline 12-lead ECG with Fridericia-corrected QT interval (QTcF) > 470 msec (female) or > 450 msec (male), a history of congenital long QT syndrome, or any ECG abnormality that, in the opinion of the Investigator, would preclude safe participation in the study
  • History of osteonecrosis of the hip or have evidence of structural bone abnormalities in the proximal femur on MRI scan that are considered clinically significant or may have an impact on the interpretation of the scan. Degenerative changes of the hip joint are not exclusionary
  • Known concomitant disease(s) known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism, Paget's disease of bone, or any other concurrent severe or uncontrolled concomitant medical condition that, in the opinion of the Investigator, would preclude participation in this study
  • Patients who are currently receiving lithium chloride (LiCl)
Both
30 Years and older
No
Contact: Diana Todd Diana.Todd@TheoremClinical.com
United States
 
NCT01711671
DEK-DKK1-P101, DKN-01, LY2812176
No
HealthCare Pharmaceuticals, Inc.
HealthCare Pharmaceuticals, Inc.
Not Provided
Study Director: Diana Todd Theorem Clinical Research
HealthCare Pharmaceuticals, Inc.
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP